DrugPatentWatch Database Preview

Litigation Details for Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

« Back to Dashboard

Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

Docket		Date Filed	2004-08-13
Court	District Court, D. Delaware	Date Terminated	2008-05-23
Cause	35:271 Patent Infringement	Assigned To	Joseph James Farnan Jr.
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICALS U.S.A., INC.; THE PROCTER & GAMBLE COMPANY
Patents	3,591,584; 4,072,746; 4,444,779; 4,621,077; 4,687,777; 5,358,941; 5,622,721; 5,681,590; 5,804,570; 5,994,329; 6,015,801; 6,090,410; 6,096,342; 6,165,513; 6,194,004; 6,465,443
Link to Docket	External link to docket

Details for Procter & Gamble Co. v. Teva Pharmaceuticals (D. Del. 2004)

Date Filed	Document No.	Description	Snippet	Link To Document
2006-12-20	100	POST Trial Brief	;s:766:	External link to document
2007-07-06	107	Exhibit	t.|iSt F’atent l\lo" 4,444,779 (the “'779 Patent”)r The ’779 patent is of particular relevance…ciaimed in the patent in suit Takeda owns U.S, Patent 4,687,777 (the "’?'77 patent") entitled… ’779 patent That patent covers a subset of compounds originally included in the '200 patent application… is not patentable fm D. “if the differences between the subject matter sought to be patented and the …court Hrst considered Takeda’s U.S. Patent 4,287,200 (the “'200 patent"), which was issued on Septernber	External link to document
2008-02-28	117	Opinion	infringed on United States Patent Nos. 5,538,122 (“the ‘122 Patent”) and 6,096,342.l (D.I. l.) On August 25…the ‘406 patent, and in particular, claim 15 of the ‘406 patent. (Teva PFF 15.) The ‘406 Patent issued …between the ‘406 Patent and ‘122 Patent, and whether such differences render the ‘122 patent obvious. The …matter claimed by the ‘122 patent and the ‘406 patent. For example, the ‘122 patent discloses the design and…double patenting. Obviousness-type double patenting, also known as non-statutory double patenting, is a	External link to document